Sara Trompeter: Improving Transfusion Safety Through Advanced Blood Matching in SCD
Sara Trompeter, Consultant Haematologist and Paediatric Haematologist at University College London Hospitals NHS Foundation Trust, Consultant Haematologist at HCA Healthcare, shared NHS Blood and Transplant‘s post on LinkedIn, adding:
“Very excited to start this study with colleagues at NHS Blood and Transplant – a potential real step in improving transfusion safety.
So grateful for the support of the wider collaboration and funders.”
NHS Blood and Transplant shared a post on LinkedIn:
“NHS Blood and Transplant (NHSBT) is leading an innovative study exploring how advanced algorithms and genomic data can transform blood matching, improving both patient safety and the use of valuable donor resources.
While current transfusion practice focuses on matching major blood groups, patients who receive frequent transfusions – including many living with sickle cell disorder – may develop immune responses to less commonly matched minor blood groups. This can lead to complications, including transfusion reactions and increasing difficulty in finding compatible blood over time.
This new feasibility study introduces bloodMatcher, an advanced algorithm that uses DNA-based genotyping from both donors and patients to enable more precise matching across a broader range of blood groups. By incorporating this genomic data, the approach aims to reduce the risk of alloimmunisation and make more effective use of rare blood units.
Led by NHSBT in partnership with University College London Hospitals NHS Foundation Trust (UCLH) and the NIHR UCLH Biomedical Research Centre, the study will evaluate the algorithm in a clinical setting, supporting around 40 patients with sickle cell disorder who require regular transfusions. Importantly, all established safety protocols will remain in place, alongside additional clinical oversight.
Dr Sara Trompeter, Consultant Haematologist at NHS Blood and Transplant and UCLH, said:
‘Currently, given the numbers of units available and orders to fulfil, it’s not practical to consider many blood types – the blood types are too complex, and the number of units too numerous , for humans to compute the best unit to send.
‘This new technology hopes to reduce the potential mismatch between donor and recipient minor blood groups. Mismatches can cause the formation of a blood group antibody (alloimmunisation) which makes it hard to find blood the patient can safely receive or even severe transfusion reactions.
‘The population cohort that most struggles with the complications of alloimmunisation is the study population of interest in this study — adults with sickle cell disorder. Around 17% of adults with sickle cell are alloimmunised.
‘The new bloodMatcher algorithm will – combined with the new genomic blood data we have available– be able to select units in a faster, far more advanced way. The goal is to improve donor to patient antigen matching and thus reduce the risk of alloimmunisation and the risk of severe transfusion reactions for patients needing blood. By improving matching, we will de facto also reduce ‘waste’, caused by giving valuable rare units to people who don’t need them.’
By combining cutting-edge AI with genomic science, this research has the potential to pave the way for a larger, multi-centre trial and, ultimately, a step change in how blood is matched for patients across the NHS.”

Stay updated with Hemostasis Today.
-
Jul 11, 2026, 21:44Timos Papagatsias: From Promising Concepts to Clinical Differentiation at ISTH 2026
-
Jul 11, 2026, 21:43Sharing New Research in Hemophilia at ISTH 2026 – Novo Nordisk Medical US
-
Jul 11, 2026, 21:41Bianca Constantin: Don’t Miss the ISTH Early Career Committee Activities
-
Jul 11, 2026, 21:38Fateme Babaha: Don’t Miss Your Favorite ISTH 2026 Sessions
-
Jul 11, 2026, 21:11Farjah Algahtani: Learning, Sharing, and Collaborating at ISTH 2026
-
Jul 11, 2026, 19:56Louise St. Germain Bannon: A Fantastic Start to ISTH 2026 and the Future of Thrombosis Research
-
Jul 11, 2026, 19:38Lynn Kloeckner: Recognizing Kirsten Lacine’s Impact on the Stroke Survivor Journey
-
Jul 11, 2026, 19:19Rens De Groot: New Proteomic Evidence Reveals Early Hemolysis During ADAMTS13 Relapse in Immune TTP
-
Jul 11, 2026, 19:01Laurent Bertoletti: Honoring the Legacy of Guy Meyer and the INNOVTE Network at ISTH 2026